Funded Biotechnology Startups in United States
50+ funded biotechnology startups in united states — recent funding rounds, disclosed amounts, and headquarters. Updated weekly, free to browse.
The 50 most recent U.S. biotechnology funding events in this dataset span mid-September through late November 2025. Geographic distribution skews heavily toward California and Massachusetts: San Diego hosts at least five companies in this window — Aspen Neuroscience ($115M Series C), VST Bio ($29M), Eclipse Bioinnovations, Tr1x ($50M), and VedaBio ($25M) — while the Boston-Cambridge corridor accounts for seven entries, anchored by Kailera Therapeutics' $600M Series B in Waltham.
Round classification is uneven: 17 of the 50 rounds are labeled "Venture - Series Unknown," limiting direct stage comparisons. Among the 33 explicitly staged deals, Seed rounds number 11 and Series A and Series B each account for 8. The three Series C closes — Colossal Biosciences ($120M, Dallas), Aspen Neuroscience ($115M, San Diego), and Lumen Bioscience ($30M, Seattle) — represent the largest-stage disclosed activity. Six entries, including Dewpoint Therapeutics (Series D, Boston) and Bambusa Therapeutics (Series A, Boston), do not disclose amounts.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Kailera Therapeutics led with a $600M Series B closed in Waltham, Massachusetts on October 19, 2025, followed by Kardigan's $254M Series B in South San Francisco. Colossal Biosciences ($120M Series C, Dallas) and Aspen Neuroscience ($115M Series C, San Diego) are the largest late-stage closes in the window, both disclosed within a month of each other.
Which U.S. cities show the most biotech funding activity in this window?
San Diego hosts at least five companies — Aspen Neuroscience, VST Bio, Eclipse Bioinnovations, Tr1x, and VedaBio. The greater Bay Area adds Hermes Biosciences, Kardigan, Ansa Biotechnologies, Until Labs, and others. The Boston-Cambridge corridor, including Waltham and Woburn, accounts for seven entries anchored by Kailera Therapeutics and Dewpoint Therapeutics.
How are rounds distributed by stage across these 50 entries?
Seventeen rounds are classified as "Venture - Series Unknown," limiting exact stage analysis. Among the 33 explicitly staged deals: Seed accounts for 11 rounds, Series A for 8, Series B for 8, Series C for 3 (Colossal Biosciences, Aspen Neuroscience, Lumen Bioscience), Series D for 2 (The EVERY Company, Dewpoint Therapeutics), and one Convertible Note (SciTech Development, $6M).
Are there recently funded biotech companies outside California and Massachusetts?
Yes. Colossal Biosciences raised $120M Series C from Dallas, TX; Sparrow Pharmaceuticals closed a $95M Series B from Portland, OR; Peptilogics raised $78M Series B from Pittsburgh, PA; and Lumen Bioscience closed a $30M Series C from Seattle, WA. Chicago accounts for two seed rounds — Clever Carnivore ($2M) and Madison Scientific ($3M).
What portion of rounds in this dataset have undisclosed funding amounts?
Six of the 50 entries do not report a dollar figure: Bambusa Therapeutics (Series A, Boston), Precision Neuroscience (New York), Aarvik Therapeutics (Seed, Fremont), RevOpsis Therapeutics (Seed, Springfield IL), Mana.bio (Seed, San Francisco), and Dewpoint Therapeutics (Series D, Boston). Disclosed totals therefore undercount actual capital deployed in the window.
How wide is the range of Series B deal sizes in U.S. biotech right now?
The eight Series B rounds span from Character Biosciences' $17M (Jersey City, NJ, September 2025) to Kailera Therapeutics' $600M (Waltham, MA, October 2025). The remaining six — Kardigan ($254M), Sparrow Pharmaceuticals ($95M), Peptilogics ($78M), Gate Bioscience ($65M), Ansa Biotechnologies ($45M), and BridGene Biosciences ($28M) — illustrate how broadly Series B sizes vary within a single sector and two-month span.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.